Regulus Therapeutics (RGLS) Tops Q2 EPS by 4c

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Anterix Inc. (ATEX) Tops Q4 EPS by 152c
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance